000 | 01912 a2200517 4500 | ||
---|---|---|---|
005 | 20250514023907.0 | ||
264 | 0 | _c20020510 | |
008 | 200205s 0 0 eng d | ||
022 | _a0085-2538 | ||
024 | 7 |
_a10.1046/j.1523-1755.2002.00192.x _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWenzel, Ulrich O | |
245 | 0 | 0 |
_aAngiotensin II infusion ameliorates the early phase of a mesangioproliferative glomerulonephritis. _h[electronic resource] |
260 |
_bKidney international _cMar 2002 |
||
300 |
_a1020-9 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAngiotensin II _xadministration & dosage |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aCell Cycle Proteins _xmetabolism |
650 | 0 | 4 |
_aCell Division _xdrug effects |
650 | 0 | 4 |
_aComplement C3 _xmetabolism |
650 | 0 | 4 | _aCyclin-Dependent Kinase Inhibitor p27 |
650 | 0 | 4 |
_aExtracellular Matrix _xmetabolism |
650 | 0 | 4 |
_aGlomerulonephritis, Membranoproliferative _xmetabolism |
650 | 0 | 4 |
_aImmunoglobulin G _xmetabolism |
650 | 0 | 4 | _aInfusion Pumps |
650 | 0 | 4 |
_aKidney Glomerulus _xmetabolism |
650 | 0 | 4 |
_aMacrophages _xpathology |
650 | 0 | 4 | _aMale |
650 | 0 | 4 |
_aMonocytes _xpathology |
650 | 0 | 4 |
_aNorepinephrine _xadministration & dosage |
650 | 0 | 4 | _aRats |
650 | 0 | 4 | _aRats, Sprague-Dawley |
650 | 0 | 4 | _aReceptor, Angiotensin, Type 1 |
650 | 0 | 4 | _aReceptor, Angiotensin, Type 2 |
650 | 0 | 4 |
_aReceptors, Angiotensin _xphysiology |
650 | 0 | 4 |
_aTransforming Growth Factor beta _xmetabolism |
650 | 0 | 4 |
_aTumor Suppressor Proteins _xmetabolism |
650 | 0 | 4 |
_aVasoconstrictor Agents _xadministration & dosage |
700 | 1 | _aThaiss, Friedrich | |
700 | 1 | _aHelmchen, Udo | |
700 | 1 | _aStahl, Rolf A K | |
700 | 1 | _aWolf, Gunter | |
773 | 0 |
_tKidney international _gvol. 61 _gno. 3 _gp. 1020-9 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1523-1755.2002.00192.x _zAvailable from publisher's website |
999 |
_c11757982 _d11757982 |